Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: GSK1838262 Extended Release Tablets, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Jasper, Alabama • San Diego, California • Hallandale, Florida + 20 more

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, cisplatin, IMRT; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 183
States / cities: Anchorage, Alaska • Auburn, California • Burbank, California + 152 more

Conditions: Narcolepsy, Obstructive Sleep Apnea
Interventions: JZP-110; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 51 more

Conditions: Arthroplasty, Replacement, Knee
Interventions: Triathlon® PS Total Knee System; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 11
States / cities: Columbus, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 7 more

Conditions: Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
Interventions: Durvalumab, Cetuximab; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Ulcerative Colitis
Interventions: Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine); Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 54
States / cities: Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more

Conditions: Venous Thromboembolism
Interventions: TAK-442, Enoxaparin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,045 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Cabozantinib Oral Tablet, Selumetinib Oral Capsule; Drug
Lead sponsor: Girish Dhall, MD; Other
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more

Conditions: Infertility
Interventions: Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Corneal Transplant Failure
Interventions: Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Interventions: 64Cu-LNTH-1363S; Combination Product
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 15 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Stanford, California + 2 more

Conditions: Heart Diseases, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 74
States / cities: Phoenix, Arizona • Burlingame, California • Los Angeles, California + 62 more

Conditions: Neuroblastoma
Interventions: 131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide; Radiation · Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Lumbar Degenerative Disc Disease
Interventions: SB-01 For Injection, Sham Needle; Drug
Lead sponsor: Spine BioPharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 296
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more

Conditions: Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions: tanezumab, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 99
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 28 more

Conditions: Excessive Sleepiness, Shift-work Disorder
Interventions: Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more

Conditions: Crohn's Disease
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: Coronado Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years to 16 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Urodynamic Studies
Interventions: Not listed
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Neuroblastoma
Interventions: Not listed
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 31 Days to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2099
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 13 more

Conditions: Sleep Disorders, Circadian Rhythm
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 39 more

Conditions: Fibromyalgia
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 26
States / cities: Phoenix, Arizona • Loma Linda, California • National City, California + 23 more

Search by objective public record fields.

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

MIBG With Dinutuximab +/- Vorinostat

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Tanezumab in Osteoarthritis Of The Hip

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Urodynamic Studies Prior to Surgery for Stress Urinary Incontinence

Neuroblastoma Biology Study

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome